Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
- Expansion of Guardant Health’s global presence
- Improvement of access to next-generation sequencing tests in the Middle East and North Africa
- Commitment to improving patient outcomes globally
- Partnership with a leading healthcare company in MENA
- None.
Insights
The strategic partnership between Guardant Health and Hikma Pharmaceuticals is poised to significantly enhance Guardant Health's market penetration in the MENA region. This collaboration is particularly noteworthy given the projected doubling of cancer cases in the area by 2040. The introduction of Guardant Health's comprehensive genomic profiling tests, including Shield™, Guardant Reveal™ and Guardant360® series, will likely address an unmet need for advanced cancer diagnostic tools in these markets.
From a market expansion perspective, the alliance leverages Hikma's established commercial network and regional expertise, which could accelerate the adoption of Guardant Health’s products. The ability to provide early cancer screening, recurrence monitoring and detailed tumor mutation profiling could lead to a paradigm shift in how oncological care is administered in the MENA region, potentially increasing the demand for precision oncology solutions. This strategic move could also serve as a benchmark for similar partnerships in other emerging markets, highlighting the importance of local expertise in global expansion strategies.
Guardant Health's portfolio expansion into the MENA region represents a significant advancement in the field of oncology. The availability of liquid and tissue biopsy tests for a range of applications from early cancer detection to recurrence monitoring offers oncologists new tools to personalize patient care. The introduction of next-generation sequencing (NGS) tests is particularly transformative as it allows for comprehensive genomic profiling, which can inform more targeted and effective treatment strategies.
For patients, the benefits are manifold; early detection through tests like Shield™ can lead to interventions at a more curable stage of cancer, while tools such as Guardant Reveal™ for minimal residual disease detection offer a non-invasive method to monitor for recurrence. The Guardant360® series provides detailed insights into the genetic makeup of tumors, which can guide the selection of therapies, including newer biologics and immunotherapies that are becoming increasingly prevalent in oncology. This approach aligns with the global trend towards precision medicine, where treatment is increasingly tailored to the individual characteristics of each patient's cancer.
The partnership between Guardant Health and Hikma Pharmaceuticals has the potential to be financially significant for both entities. For Guardant Health, the expansion into the MENA region represents a strategic move to tap into a growing market where the demand for advanced cancer diagnostics is expected to rise sharply. The financial implications of this partnership could be reflected in increased revenue streams from a new customer base and the potential for market leadership in precision oncology diagnostics in the region.
Hikma Pharmaceuticals, with its robust oncology portfolio and presence in the MENA market, stands to benefit from the addition of cutting-edge NGS diagnostics to its offerings. This could enhance Hikma's competitive positioning and potentially lead to increased market share in the oncology sector. For investors, the key metrics to watch would be the adoption rates of these diagnostic tests in the MENA region, the impact on Guardant Health's international revenues and the overall financial performance of both companies as a result of this partnership.
The partnership expands Guardant Health’s global presence and includes products across the cancer care continuum. The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant’s next-generation sequencing (NGS) tests in the
“Guardant Health is excited to partner with Hikma and leverage their strong commercial capabilities and regional expertise to equip oncologists in MENA with the necessary tools for cancer screening, recurrence monitoring and guiding treatment selection,” said Simranjit Singh, Guardant Health AMEA CEO. “We are committed to improving patient outcomes globally by offering next-generation sequencing tests across all stages of the disease. Today, an increasing number of patients with cancer are being detected at the advanced stage, making it more crucial to match these patients to appropriate therapies in a timely manner. Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable.”
“Our partnership with Guardant Health adds next-generation sequencing diagnostics that can potentially transform cancer care in MENA bringing hope to patients facing this challenging journey. We are excited to partner with Guardant Health, as their offering can help patients at all stages of the disease – from screening to monitoring cancer recurrence to guiding treatment decisions. As a leading healthcare company in MENA with a robust oncology portfolio encompassing generics, biologics, immunotherapy, and cutting-edge innovations, Hikma is committed to advancing precision medicine for improved treatment outcomes in patients with cancer," said Mazen Darwazah, Hikma’s executive vice chairman and president of MENA.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the
Reference
1. Mahdi H, Mula-Hussain L, Ramzi ZS, et al. Cancer Burden Among Arab-World Females in 2020: Working Toward Improving Outcomes. JCO Glob Oncol. 2022;8:e2100415. doi:10.1200/GO.21.00415
View source version on businesswire.com: https://www.businesswire.com/news/home/20240107941841/en/
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com
Mona Abdallah
Senior Director, MENA Communications
+ 962 6 5802900
MBAbdallah@Hikma.com
Guardant Health
Investor Contact:
investors@guardanthealth.com
Media Contacts:
Melissa Marasco
Senior Corporate Communications Manager
press@guardanthealth.com
+1 650-647-3711
Prakash Raja
Senior Manager Communications AMEA
press_amea@guardanthealth.com
+65 90051001
Source: Guardant Health, Inc.
FAQ
What is the partnership between Guardant Health and Hikma about?
What are the specific tests offered by Guardant Health in this partnership?
What is the goal of Guardant Health in this partnership?
What is Hikma's role in the partnership?
